Last10K.com

Amphastar Pharmaceuticals, Inc. (AMPH) SEC Filing 10-Q Quarterly report for the period ending Tuesday, June 30, 2020

Amphastar Pharmaceuticals, Inc.

CIK: 1297184 Ticker: AMPH

EXHIBIT 99.1

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2020

Reports Net Revenues of $85.8 Million for the Three Months Ended June 30, 2020

RANCHO CUCAMONGA, CA – August 6, 2020 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2020.

Second Quarter Highlights

Net revenues of $85.8 million for the second quarter
GAAP net loss of $0.2 million, or $0.00 per share, for the second quarter
Adjusted non-GAAP net income of $7.6 million, or $0.16 per share, for the second quarter

Dr. Jack Zhang, Amphastar’s President and Chief Executive Officer, commented: “We are pleased with Amphastar’s second quarter and the first half of the year so far. Primatene® Mist has been a strong performer for the Company, while our epinephrine multi-dose vial launch continues to gain momentum. Despite the challenges presented by the COVID-19 pandemic, we remain confident, heading into our catalyst-rich second half of the year.”

Three Months Ended

Six Months Ended

 

June 30, 

June 30, 

 

2020

2019

2020

2019

 

(in thousands, except per share data)

 

Net revenues

    

$

85,806

    

$

79,047

    

$

170,494

    

$

158,837

GAAP net (loss) income attributable to Amphastar

$

(192)

$

47,787

$

3,757

$

48,655

Adjusted non-GAAP net income attributable to Amphastar*

$

7,610

$

4,117

$

15,993

$

9,002

GAAP diluted EPS attributable to Amphastar shareholders

$

(0.00)

$

0.96

$

0.08

$

0.97

Adjusted non-GAAP diluted EPS attributable to Amphastar shareholders*

$

0.16

$

0.08

$

0.33

$

0.18


The following information was filed by Amphastar Pharmaceuticals, Inc. (AMPH) on Thursday, August 6, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Amphastar Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Amphastar Pharmaceuticals, Inc..

Continue

Assess how Amphastar Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Amphastar Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Financial
M & A
Other
Filter Subcategory:
All
Product
Expense
Geography
Cash Flow
Other
Inside Amphastar Pharmaceuticals, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income (Loss)
Condensed Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity
(Loss) Income Per Share Attributable To Amphastar Pharmaceuticals, Inc. Shareholders
(Loss) Income Per Share Attributable To Amphastar Pharmaceuticals, Inc. Shareholders (Calculation Of Basic And Diluted Net Income (Loss) Per Share) (Details)
(Loss) Income Per Share Attributable To Amphastar Pharmaceuticals, Inc. Shareholders (Narrative) (Details)
(Loss) Income Per Share Attributable To Amphastar Pharmaceuticals, Inc. Shareholders (Tables)
Accounts Payable And Accrued Liabilities
Accounts Payable And Accrued Liabilities (Details)
Accounts Payable And Accrued Liabilities (Tables)
Commitments And Contingencies
Commitments And Contingencies (Purchase Commitments) (Details)
Customer And Supplier Concentration
Customer And Supplier Concentration (Details)
Customer And Supplier Concentration (Tables)
Debt
Debt (Narrative) (Details)
Debt (Schedule Of Debt) (Details)
Debt (Tables)
Employee Benefits
Employee Benefits (Details)
Fair Value Measurements
Fair Value Measurements (Fair Values Of The Company's Financial Assets And Liabilities) (Details)
Fair Value Measurements (Tables)
General
Goodwill And Intangible Assets
Goodwill And Intangible Assets (Summary Of Changes In The Carrying Amount Of Goodwill) (Details)
Goodwill And Intangible Assets (Summary Of Intangible Assets) (Details)
Goodwill And Intangible Assets (Tables)
Income Taxes
Income Taxes (Summary Of Income Before Taxes) (Details)
Income Taxes (Tables)
Inventories
Inventories (Details)
Inventories (Tables)
Investments
Investments (Held-To_Maturity) (Details)
Investments (Tables)
Litigation
Litigation (Details)
Property, Plant, And Equipment
Property, Plant, And Equipment (Summary Of Property, Plant, And Equipment) (Details)
Property, Plant, And Equipment (Tables)
Revenue Recognition
Revenue Recognition (Analysis Of Product Return Liability) (Details)
Revenue Recognition (Analysis Of The Chargeback Provision) (Details)
Revenue Recognition (Tables)
Segment Reporting
Segment Reporting (Depreciation And Amortization Expense By Reporting Segment) (Details)
Segment Reporting (Selected Financial Information By Reporting Segment) (Details)
Segment Reporting (Summary Of Net Revenues By Product Segment) (Details)
Segment Reporting (Summary Of Revenues And Long-Lived Assets By Geographic Region) (Details)
Segment Reporting (Tables)
Stockholders' Equity
Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details)
Stockholders' Equity (Information Relating To Option Grants And Exercises) (Details)
Stockholders' Equity (Information Relating To Rsu Grants And Deliveries) (Details)
Stockholders' Equity (Key Assumptions Used In Determining Fair Value Of Options Granted) (Details)
Stockholders' Equity (Restricted Stock Units) (Details)
Stockholders' Equity (Share Buyback Program) (Details)
Stockholders' Equity (Share-Based Compensation Expense Included In The Statement Of Operations) (Details)
Stockholders' Equity (Summary Of Nonvested Options) (Details)
Stockholders' Equity (Summary Of Option Activity) (Details)
Stockholders' Equity (Tables)
Stockholders' Equity (The 2015 Equity Incentive Plan) (Details)
Stockholders' Equity (The 2018 Anp Equity Incentive Plan) (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Ticker: AMPH
CIK: 1297184
Form Type: 10-Q Quarterly Report
Accession Number: 0001297184-20-000047
Submitted to the SEC: Fri Aug 07 2020 6:32:44 PM EST
Accepted by the SEC: Mon Aug 10 2020
Period: Tuesday, June 30, 2020
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/amph/0001297184-20-000047.htm